Hit enter to search or ESC to close
Talis
  • Solution
  • Company
  • Careers
  • Investors
  • Contact
PR
February 17, 2021

Talis Announces Closing of Initial Public Offering and
Full Exercise of Underwriters’ Option to Purchase Additional Shares

MENLO PARK, CALIF., Wednesday, February 17, 2021 – Talis Biomedical Corporation (Nasdaq: TLIS), a company…
Talis
Love0
PR
February 12, 2021

Talis Announces Pricing of Initial Public Offering

MENLO PARK, Calif., Feb. 11, 2021 (GLOBE NEWSWIRE) -- Talis Biomedical Corporation (Nasdaq: TLIS), a…
Talis
Love0
PR
January 27, 2021

Talis Appoints Melissa L. Gilliam, M.D., M.P.H., to Board of Directors

Clinician and Academician Brings Expertise in Women’s and Adolescents’ Health and Focus on Diversity, Equity,…
Talis
Love0
PR
November 11, 2020

Talis Expands Executive Team and Closes Additional Financing in Preparation for Commercial Launch of Talis One™ System

MENLO PARK, CALIF. – November 12, 2020 – Talis Biomedical Corporation, a company dedicated to…
Talis
Love0
PR
July 31, 2020

Talis Awarded NIH RADx Contract to Launch Talis One™ System for Point-of-Care COVID-19 Testing and Further Strengthens Financial Position and Leadership Team

Company awarded $25 million in NIH RADx contract and secures $100 million new financing  Industry…
Talis
Love0
PR
October 11, 2018

Talis Biomedical Corporation announces expansion of Scientific Advisory Board

Jane Schwebke, M.D., joins the Talis SAB MENLO PARK, Calif., Oct. 11, 2018 /PRNewswire/ --…
Talis
Love1
PR
August 29, 2018

Talis Biomedical Corporation awarded $5.6M by NIH

Talis Bio is developing a high-performance molecular point-of-care (POC) diagnostic platform to enable physician offices and…
Talis
Love2
PR
August 29, 2018

Talis Bio awarded $4.4M by CARB-X

Talis is developing a high-performance diagnostic platform to enable physician offices and clinics to run reference…
Talis
Love0

Talis One and the Talis One COVID-19 Assay for use in CLIA high/moderate complexity settings have been submitted to FDA for Emergency Use Authorization (EUA). A point-of-care (POC) solution for use in CLIA-waived settings and additional assays are in development.

  • Home
  • Solution
  • Company
  • Careers
  • Investors
  • Contact
Talis Biomedical

Menlo Park
230 Constitution Dr.
Menlo Park, CA 94025

Chicago
125 S Clark Street, 17th Floor
Chicago, IL 60603

info@talisbio.com
650-433-3000

© 2021 Talis and Talis One are trademarks of Talis Biomedical.

  • Solution
  • Company
  • Careers
  • Investors
  • Contact